[Use of cerebrolysin in the treatment of prolonged extrapyramidal complications of neuroleptic therapy].
Open study was performed concerning the efficiency of cerebrolysin in treatment of tardive dyskinesia and parkinsonism. 30 patients of middle (18-41 years) and old (60-82 years) age were examined by means of Extrapyramidal Symptom Rating Scale and Abnormal Involuntary Movement Scale. Cerebrolysin was administered intravenously by drops every other day in a dose of 5-10 ml during 28 days. Significant decrease of the severity of extrapyramidal symptoms (according to the Scales used) was observed by the end of the course of therapy. The number of the responders was 46.6%, of the partial responders--26.6%. Efficiency of cerebrolysin was the same both in the groups of patients with drug-induced parkinsonism (number of the responders--54.5%) and in patients with tardive dyskinesia (the responders' number--60%). The efficiency of cerebrolysin was lower in patients with combination of symptoms of parkinsonism and tardive dyskinesia as well as in ones with pronounced negative schizophrenic disorders in clinical picture. Efficacy of cerebrolysin was also the same in patients of both middle and old age. Its efficiency was equally high independently on the duration of extrapyramidal disorders' existence.
Kontsevoĭ
V A
VA
Medvedev
A V
AV
Andrusenko
M P
MP
Zvenigorodskaia
Iu V
IuV
Sheshenin
V S
VS
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000596:Amino Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D020734:Parkinsonian Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors
D000596:Amino Acids; D014150:Antipsychotic Agents; D018696:Neuroprotective Agents; D018697:Nootropic Agents; C006952:cerebrolysin
Ispol'zovanie tserebrolizina dlia lecheniia zatiazhnykh ékstrapiramidnykh oslozhneniĭ neĭrolepticheskoĭ terapii.